Burosumab in X-linked hypophosphatemia: a profile of its use in the USA

Burosumab (Crysvita(®)), a fully human IgG1 monoclonal antibody directed at fibroblast growth factor 23 (FGF23), is indicated for the treatment of X-linked hypophosphatemia (XLH), a condition associated with excessive FGF23 production. It directly addresses the excessive FGF23 activity in patients w...

Descripción completa

Detalles Bibliográficos
Autor principal: Lyseng-Williamson, Katherine A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Adis Drug Q&A
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223702/
https://www.ncbi.nlm.nih.gov/pubmed/30459508
http://dx.doi.org/10.1007/s40267-018-0560-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223702/
https://www.ncbi.nlm.nih.gov/pubmed/30459508
http://dx.doi.org/10.1007/s40267-018-0560-9

Ejemplares similares